Fibrobiologics, INC. (FBLG) — 8-K Filings

8-K Filings (26)

• FibroBiologics Files 8-K: Material Agreement, Equity Sales — Dec 15, 2025 Risk: medium
  FibroBiologics, Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 14, 2025. The filing indicates a material definitive agree
• 8-K Filing — Nov 25, 2025
• 8-K Filing — Nov 19, 2025
• FibroBiologics Faces Delisting Concerns — Aug 8, 2025 Risk: high
  FibroBiologics, Inc. filed an 8-K on August 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the effect
• FibroBiologics Reports Unregistered Equity Sales — Jul 18, 2025 Risk: medium
  FibroBiologics, Inc. filed an 8-K on July 18, 2025, reporting unregistered sales of equity securities that occurred on June 20, 2025. The filing details the com
• FibroBiologics Faces Listing Rule Issues — Jul 3, 2025 Risk: high
  FibroBiologics, Inc. filed an 8-K on July 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of
• FibroBiologics Files 8-K: Agreements, Obligations, Equity Sales — Jun 16, 2025 Risk: medium
  On June 16, 2025, FibroBiologics, Inc. filed an 8-K report detailing a material definitive agreement, the creation of a direct financial obligation, unregistere
• FibroBiologics Files 8-K on Shareholder Votes & Bylaws — Jun 13, 2025 Risk: low
  FibroBiologics, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders and amendments to its articles of incorporation
• FibroBiologics Appoints New CMO, Adds Directors — Jun 9, 2025 Risk: medium
  FibroBiologics, Inc. announced on June 9, 2025, the appointment of Dr. Robert L. Johnson as Chief Medical Officer and the election of Dr. Johnson and Ms. Karen
• FibroBiologics Appoints New CEO, Adds Director, Restructures Executive Roles — May 5, 2025 Risk: medium
  FibroBiologics, Inc. announced on May 2, 2025, a series of executive and board changes. Dr. Jonathan Webb has been appointed as Chief Executive Officer, and Dr.
• FibroBiologics Files 8-K on Equity Sales — Feb 7, 2025 Risk: medium
  On January 7, 2025, FibroBiologics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included financial statements an
• FibroBiologics Appoints New CMO, Adds Director — Jan 24, 2025 Risk: medium
  FibroBiologics, Inc. announced on January 23, 2025, the appointment of Dr. Jonathan L. R. Roth as Chief Medical Officer and the election of Dr. David M. Epstein
• FibroBiologics Files 8-K: Agreements, Equity, and Personnel Changes — Dec 31, 2024 Risk: medium
  On December 27, 2024, FibroBiologics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on th
• FibroBiologics Files 8-K: Agreements, Obligations, and Equity Sales — Dec 23, 2024 Risk: medium
  On December 20, 2024, FibroBiologics, Inc. entered into a material definitive agreement related to a direct financial obligation. The company also reported on t
• FibroBiologics Files 8-K: Agreements, Equity Sales — Dec 20, 2024 Risk: medium
  On December 19, 2024, FibroBiologics, Inc. entered into a material definitive agreement with an undisclosed party. The company also reported on the termination
• FibroBiologics Board Shake-up: New Director Elected, Officer Compensation Noted — Oct 29, 2024 Risk: medium
  FibroBiologics, Inc. announced on October 25, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dr. Jonatha
• FibroBiologics, Inc. Enters Material Definitive Agreement — Sep 24, 2024 Risk: medium
  On September 19, 2024, FibroBiologics, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its
• FibroBiologics Files 8-K on Corporate Actions — Aug 28, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on August 27, 2024, reporting on several key corporate actions. These include amendments to its articles of incorporation or b
• FibroBiologics Files 8-K for Equity Sale — Aug 27, 2024 Risk: medium
  FibroBiologics, Inc. announced on August 26, 2024, the unregistered sale of equity securities. The company filed an 8-K report detailing this event, which also
• FibroBiologics Relocates Offices, Updates Contact Info — Jun 27, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on June 27, 2024, reporting a change in its principal executive offices to 455 E. Medical Center Blvd., Suite 300, Houston, Te
• FibroBiologics Files 8-K Report — Apr 26, 2024 Risk: low
  On April 26, 2024, FibroBiologics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mate
• FibroBiologics Files 8-K on Other Events and Financial Exhibits — Feb 20, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on February 20, 2024, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates a current repo
• FibroBiologics Files 8-K for Unspecified Events and Exhibits — Feb 14, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on February 14, 2024, reporting an earliest event date of February 13, 2024. The filing indicates 'Other Events' and 'Financia
• FibroBiologics Files 8-K, Confirms Emerging Growth Status — Feb 8, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on February 8, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. This filing indicates that the compan
• FibroBiologics 8-K: Emerging Growth Co. Opts Out of Accounting Grace Period — Feb 6, 2024
  FibroBiologics Inc. filed an 8-K on February 6, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates that the company i
• FibroBiologics Confirms Emerging Growth Company Status in 8-K — Feb 2, 2024
  FibroBiologics Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on January 31, 2024. The filing indicates that FibroBiologics is an emerg

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX